Acadia Pharmaceuticals announced that Doug Williamson, M.D., Executive Vice President, Head of Research and Development, will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $40 from $38 at Canaccord
- Mizuho upgrades Acadia to Buy on strengthening fundamentals
- Acadia Pharmaceuticals upgraded to Buy from Neutral at Mizuho
- Acadia Pharmaceuticals price target raised to $42 from $39 at JMP Securities
- Acadia Pharmaceuticals sees FY23 NUPLAZID net sales $537.5M-$545M